Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Orchid Cellmark Awarded Forensic DNA Contracts

By Labmedica staff writers
Posted on 11 Oct 2006
Orchid Cellmark Inc., a provider of identity DNA testing services, has announced that its UK operation, Orchid Cellmark Ltd., (Abingdon, UK), has been awarded new DNA contracts with police forces in Kent, Sussex, and London.

Orchid Cellmark was awarded a three-year exclusive contract to provide DNA testing for PACE (Police and Criminal Evidence Act) and crime scene stain-profiling services for Kent and Sussex police forces. More...
There is an option to extend the contract for an additional two years. The company will also provide DNA testing services for PACE mouth swab samples for police in London. The contract is for five years.

The crime scene stain service provided to Kent and Sussex police forces involves the DNA analysis of items recovered from crimes such as burglary and car theft. There are usually no suspects in these cases and any resulting profiles are submitted to the UK National DNA Database for intelligence purposes. The shorter the time interval between the offense date and provision of intelligence from the UK National DNA Database, the greater the chance of police recovering property belonging to a complainant for offenses such as burglary.

The UK operation of Orchid Cellmark provides British customers with a full range of forensic DNA services. From the routine testing of DNA samples for submission to the National DNA Database to the collection and analysis of evidence for the investigation of the most serious crimes, Orchid Cellmark is capable of attaining results from particularly small and compromised samples. The company currently provides most of its forensic DNA services in the United Kingdom through a subcontract relationship with Forensic Alliance Ltd. This relationship is being terminated and the company is now providing its services directly to UK police forces.

Thomas Bologna, president and CEO of Orchid Cellmark Inc., commented, "We believe our DNA forensic operations in the UK are second to none in providing innovation, quality, and rapid testing turnaround time, and we are very pleased that these three important police forces have awarded contracts to Orchid Cellmark. Equally important, we believe that obtaining this business suggests that our plan to provide forensic services directly to UK police forces is proceeding well.”



Related Links:
Orchid Cellmark

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.